Search

Your search keyword '"Filipski K"' showing total 49 results

Search Constraints

Start Over You searched for: Author "Filipski K" Remove constraint Author: "Filipski K"
49 results on '"Filipski K"'

Search Results

4. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

5. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum

9. Cisplatin-Induced Downregulation of OCTN2 Affects Carnitine Wasting

14. Updating the landscape of direct-to-consumer pharmacogenomic testing

15. Dual MAPK Inhibition Triggers Pro-inflammatory Signals and Sensitizes BRAF V600E Glioma to T Cell-Mediated Checkpoint Therapy.

16. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment.

17. A flow cytometry-based protocol for syngenic isolation of neurovascular unit cells from mouse and human tissues.

18. DNA methylation subclasses predict the benefit from gross total tumor resection in IDH-wildtype glioblastoma patients.

19. Longitudinal study on MRI and neuropathological findings: Neither DSC-perfusion derived rCBVmax nor vessel densities correlate between newly diagnosed and progressive glioblastoma.

20. Evaluation of automatic discrimination between benign and malignant prostate tissue in the era of high precision digital pathology.

21. HIP1R and vimentin immunohistochemistry predict 1p/19q status in IDH-mutant glioma.

22. Immunotherapy approaches for the treatment of diffuse midline gliomas.

23. Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.

24. Profiling the neurovascular unit unveils detrimental effects of osteopontin on the blood-brain barrier in acute ischemic stroke.

25. Sex-Dependent Analysis of Temozolomide-Induced Myelosuppression and Effects on Survival in a Large Real-life Cohort of Patients With Glioma.

26. Neurocognitive Outcome and Seizure Freedom After Awake Surgery of Gliomas.

27. Immune profile and radiological characteristics of progressive multifocal leukoencephalopathy.

28. Immune Checkpoint Inhibitor-Induced Cerebral Pseudoprogression: Patterns and Categorization.

29. PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum.

30. A 25-year retrospective, single center analysis of 343 WHO grade II/III glioma patients: implications for grading and temozolomide therapy.

31. DNA methylation-based prediction of response to immune checkpoint inhibition in metastatic melanoma.

32. TERT promoter mutation and chromosome 6 loss define a high-risk subtype of ependymoma evolving from posterior fossa subependymoma.

33. Sequential implementation of DSC-MR perfusion and dynamic [ 18 F]FET PET allows efficient differentiation of glioma progression from treatment-related changes.

34. Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma.

35. Gliomatosis Cerebri Growth Pattern: Association of Differential First-Line Treatment with Overall Survival in WHO Grade II and III Gliomas.

36. The ability to return to work: a patient-centered outcome parameter following glioma surgery.

37. Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort.

38. 18 F-FET PET Imaging in Differentiating Glioma Progression from Treatment-Related Changes: A Single-Center Experience.

39. Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients.

40. Ceritinib-Induced Regression of an Insulin-Like Growth Factor-Driven Neuroepithelial Brain Tumor.

41. Lack of H3K27 trimethylation is associated with 1p/19q codeletion in diffuse gliomas.

42. Distribution and prognostic impact of microglia/macrophage subpopulations in gliomas.

43. IGF1R Is a Potential New Therapeutic Target for HGNET-BCOR Brain Tumor Patients.

44. [Hypertrophic olivary degeneration : Cause of new neurological symptoms after stroke].

45. Contrast enhancing spots as a new pattern of late onset pseudoprogression in glioma patients.

46. Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.

47. The Clinical Sequencing Evidence-Generating Research Consortium: Integrating Genomic Sequencing in Diverse and Medically Underserved Populations.

48. Implementation of the 21-gene recurrence score test in the United States in 2011.

49. Bitter triggers acetylcholine release from polymodal urethral chemosensory cells and bladder reflexes.

Catalog

Books, media, physical & digital resources